Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

Key facts

Sponsor

Li Shiyue

Intervention

MSC-exos Nebulization Therapy(drug)

Enrollment

10 enrolled

Eligibility

18-75 years · All sexes

Timeline

2025 – 2027

Study locations (1)

• The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dermatomyositis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07111065
  FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
  National Institute of Environmental Health Sciences (NIEHS)
• ACTIVE NOT RECRUITINGNCT07531446
  Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters
  Ruijin Hospital
• RECRUITINGPHASE2, PHASE3NCT07160205
  Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
  Restem, LLC.
• RECRUITINGNANCT07377058
  RCT of Tocilizumab for Anti-MDA5+DM
  Peking Union Medical College Hospital
• RECRUITINGNCT07345949
  Panniculitis in Dermatomyositis
  University Hospital, Strasbourg, France
• RECRUITINGPHASE2NCT06857240
  Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
  The Cleveland Clinic
• RECRUITINGPHASE2NCT06672822
  Intralesional Injection of STS in Treatment of Calcinosis
  Robyn T. Domsic, MD, MPH
• RECRUITINGPHASE3NCT06698796
  A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
  Pfizer

See all trials for Dermatomyositis →